All In Biotech

NDA 021164 · Fabre Kramer

Exxua

Gepirone Hydrochloride · Oral

Novel

CDER novel approval, Sep 22, 2023: To treat major depressive disorder

Last checked: Nov 20, 2026Latest source record: Jun 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 22, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 0 recruiting

FAERS reports

4

1 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1 ) ] . EXXUA is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants. Closely monitor for worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). EXXUA is not approved for use in pediatric patients ( 8.4 ).

What it is approved for

From the label in effect Jul 14, 2026.

EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults. EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ).

Mechanism: The mechanism of the antidepressant effect of EXXUA is not fully understood but is thought to be related to its modulation of serotonergic activity in the CNS through selective agonist activity at 5HT1A receptors.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 22, 2023 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
4 products under this application
  • EXXUA · GEPIRONE HYDROCHLORIDE EQ 54.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • EXXUA · GEPIRONE HYDROCHLORIDE EQ 18.2MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • EXXUA · GEPIRONE HYDROCHLORIDE EQ 72.6MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • EXXUA · GEPIRONE HYDROCHLORIDE EQ 36.3MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gepirone" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • panic attack2
  • anger1
  • anxiety1
  • blood pressure increased1
  • drug ineffective1
  • headache1
  • illness1
  • insomnia1
  • migraine1
  • muscle twitching1
  • nervousness1
  • overdose1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 34 on PubMed

Sponsor: Fabre Kramer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.